

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**PuraPharm**

**PURAPHARM CORPORATION LIMITED**

**培力控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1498)**

**RE-DESIGNATION OF NON-EXECUTIVE DIRECTOR  
AS EXECUTIVE DIRECTOR AND CHANGE OF  
THE COMPOSITION OF AUDIT COMMITTEE**

The board of directors (the “Board” or “Directors”) of PuraPharm Corporation Limited (the “Company”, together with its subsidiaries, the “Group”) announces that with effect from 15 November 2017, Mr. Chan Kin Man, Eddie (“Mr. Eddie Chan”) has been re-designated from a non-executive Director to an executive Director.

Mr. Eddie Chan has over 30 years of extensive experience in professional accounting and taxation services. He is the founder and senior partner in CWCC, an accounting firm, to oversee the divisions of tax, corporate secretarial and China business advisory services. Mr. Eddie Chan was accredited as a Certified Public Accountant (practising) and a fellow member by the Hong Kong Institute of Certified Public Accountants in January 1990 and July 1993 respectively, a Chartered Certified Accountant (practising) and a fellow member of the Association of Chartered Certified Accountants in July 2004 and January 2001 respectively. He has been an associate member of The Institute of Chartered Accountants in England and Wales since December 2007. He received a higher diploma in accountancy from the Hong Kong Polytechnic University.

In light of the re-designation, Mr. Eddie Chan has entered into a service contract as an executive Director with the Company for a term of three year commencing from 15 November 2017 renewable following the expiration of the term. He will hold office until the next general meeting of the Company and is subject to retirement by rotation and re-election of the annual general meeting of the Company in accordance with the articles of association of the Company. He will be entitled to receive a fixed annual director’s fee of HK\$200,000, which was determined with reference to his experience and qualification, his duties and responsibilities in the Group, and the prevailing market conditions.

As at the date of this announcement, Mr. Eddie Chan was beneficially interested in 3,145,000 shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, Mr. Eddie Chan has no relationships with any Directors, senior management, substantial or controlling shareholders of the Company and there are no matters relating to the aforesaid re-designation that need to be brought to the attention of the shareholders of the Company, nor is there any other information required to be disclosed pursuant to Rule 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

## **CHANGE OF THE COMPOSITION OF AUDIT COMMITTEE**

Following the re-designation of Mr. Eddie Chan from a non-executive Director to an executive Director and his resignation as member of the audit committee of the Board on 15 November 2017, Dr. Chan Kin Keung, Eugene, an independent non-executive Director, was appointed as member of the audit committee of the Board on the same day and the current composition of the audit committee of the Board is as follow:

Mr. Ho Kwok Wah, George (*Chairman*)

Dr. Chan Kin Keung, Eugene

Dr. Leung Lim Kin, Simon

The Board would like to take this opportunity to express its gratitude towards Mr. Eddie Chan for his contribution as a non-executive Director in the past and look forward to his continuous contribution to the Group as an executive Director.

By Order of the Board  
**PuraPharm Corporation Limited**  
**Chan Yu Ling, Abraham**  
*Chairman*

Hong Kong, 15 November 2017

*As at the date of this announcement, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Mr. Chan Kin Man, Eddie, Mr. Chan Lung Sang and Ms. Man Yee Wai, Viola; and the independent non-executive directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.*